Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib. … To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.

  2. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis. … This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia.

  3. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … If Chagas disease is left untreated, life-threatening sequelae may result.[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease.

  4. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic

    Categories: Vasodilators Used in Cardiac Diseases
  5. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]

  6. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    It is prepared by the reaction of gluconic acid solutions with cupric oxide or basic cupric carbonate. … According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

    Mixtures: Iron, Vit & Min Supp, Children's Chew Multi & Min Tab
  7. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

  8. Drug

    Thiram

    go.drugbank.com/drugs/DB13245
    Approved

    Thiram may be used in dermatology as a scabicide [T436]. … Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. … It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: Tiomolibdate ion
  10. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures … in adult patients with refractory epilepsy.

    Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester